Browse diseases

…sis in response to aberrant growth signals. Paradoxically, many cancers overexpress these proteins when downstream effectors that enfor…

…have died, now survive—those with, for example, some cancers or ischaemic heart disease. In many cases, they live productive lives for another 15 years…

…uscle strength decline is reported to predict mortality in many cancers. However, there is little knowledge of the relation between mus…

…y in oncology, where it is still measurable in survival in many cancers. It can be trickier in other things, like moderate asthma contr…

…e an essential therapeutic strategy in the treatment of various cancers. However, the variability in patients’ response remains a major…

…vailable recombinant IL-2 as a therapeutic for several types of cancers. The availability of recombinant IL-2 has also enabled the deve…

… responses.Methods Bria-OTS+ cell lines targeting lung, breast, melanoma, and prostate cancers were genetically engineered to express im…

…cers once considered untreatable. However, its effectiveness in solid tumors is often limited by multifactorial T cell dysfunction, particul…

…17% (3/18) with AdAPT-001 + CI. Particular activity was seen in angiosarcoma, where all patients progressed within 3 months on Prior CI and …

…ansfer of Fli1 KO T cells significantly delayed tumor growth in MC38-OVA and B16-F10 melanoma models in vivo, with increased T cell infi…

…signaling. Although they have shown clinical utility in certain cancers, type I IFNs face limitations due to poor stability, short half…

…ave shown great promise as immunotherapeutic molecules to treat cancers. TCEs can redirect T cells to recognize and kill cancer cells t…